We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer (Biobank)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01084785
Recruitment Status : Recruiting
First Posted : March 11, 2010
Last Update Posted : May 24, 2016
Information provided by (Responsible Party):

March 10, 2010
March 11, 2010
May 24, 2016
January 2003
January 2025   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01084785 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer
Storing Blood for Analysis of DNA and Protein of Patients With Cancer in MAASTRO Clinic
The purpose of this study is to determine, by means of DNA and protein analysis, the relationship between DNA and protein profiles and a number of endpoints, which are important for the patient such as overall survival and side effects.
It has already been known for a long time that cancer is a genetic disorder and that the development of the illness is a very complex interaction between genetic and surrounding factors. Also the response on therapy and the development and seriousness of side effects is stipulated by this complicated collaboration of genetic and surrounding factors. Moreover it is not only the DNA that plays an important role but also the systems of control at protein level. At this moment a lot of questions remain to be answered because up till now the studies were of rather restricted statistic strength with frequently inconsistent dates and moreover retrospective. Major retrospective studies are necessary to distinguish the relationship between DNA/protein patterns and clinical relevant endpoints like prognosis and toxicity in which an as broad as possible patient group is being monitored. For this reason we want to take blood samples in MAASTRO clinic of all patients with lung cancer and to store it encrypted so that we can perform DNA and protein analyses in future and to correlate the results with survival and toxicity of the treatment.
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
whole blood
Non-Probability Sample
primary care clinic
Not Provided
Not Provided
Dehing-Oberije C, Aerts H, Yu S, De Ruysscher D, Menheere P, Hilvo M, van der Weide H, Rao B, Lambin P. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):360-8. doi: 10.1016/j.ijrobp.2010.06.011. Epub 2010 Oct 1.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
January 2025
January 2025   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • cancer

Exclusion Criteria:

  • not able to comply with follow-up
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact: Philippe Lambin, Prof PHD 31 (0) 088 44 55 666 philippe.lambin@maastro.nl
Contact: Dirk De Ruysscher, Prof PHD 31 (0) 088 44 55 666 dirk.deruysscher@maastro.nl
Not Provided
Not Provided
Maastricht Radiation Oncology
Maastricht Radiation Oncology
Maastricht University Medical Center
Principal Investigator: Dirk De Ruysscher, Prof PHD CCMO
Maastricht Radiation Oncology
May 2016